ONCOLOGY Vol 25 No 10 | Oncology

What Are Safe Margins of Resection for Invasive and In Situ Breast Cancer?

September 15, 2011

The safety and efficacy of breast-conserving therapy (BCT) for women with early-stage breast cancer are well established. BCT entails wide excision of the tumor and appropriate nodal evaluation, followed by radiation therapy to the breast.

Bladder Cancer: Imperatives for Personalized Medicine

September 15, 2011

Wide variations in the care of early bladder cancer exist, and among high–treatment intensity urology providers, overall survival is unchanged while rates of transition to major surgery are actually increasing. It has been said that for bladder tumors, it is time for a paradigm shift. We believe that the time is overdue.

Cancer-Related TTP and Considerations of Plasma Exchange

September 13, 2011

The diagnosis and therapy of thrombotic thrombocytopenic purpura (TTP) have advanced dramatically in the past 25 years, with increasing diagnostic awareness spurred on by the discovery of plasma exchange as an effective therapy.

Is Neoadjuvant Chemotherapy in Ovarian Cancer an Excuse for Insufficient Surgery?

September 13, 2011

Surgical debulking of epithelial ovarian carcinoma has been a mainstay of therapy for more than 50 years-since the approach was first advocated by Meigs in 1934.[1] In 1968, Munnell[2] introduced the idea of the "maximum surgical effort”-essentially the removal of as much cancer as possible.

Ginkgo (Ginkgo biloba)

September 13, 2011

Ginkgo biloba, one of the oldest living tree species, is cultivated worldwide for its medicinal properties and aesthetic appeal. The leaves and seeds are used in traditional medicine to treat respiratory diseases, circulatory disorders, sexual dysfunction, and loss of hearing.

FDA Approves Brentuximab Vedotin for Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma

August 25, 2011

The U.S. Food and Drug Administration (FDA) announced last week the approval of brentuximab vedotin, a CD30-directed antibody drug-conjugate, for the treatment of refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma.

FDA Approves Vemurafenib for Treatment of Metastatic Melanoma

August 19, 2011

The U.S. Food and Drug Administration approved vemurafenib (Zelboraf) for the treatment of metastatic or unresectable melanoma. The new drug, also known as PLX4032, specifically targets patients whose tumors express the BRAF V600E gene mutation.